Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Additional considerations include the comfort of the subject
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
Related Articles - Research Library Explore the Science Behind This System The Research Library provides in-depth editorial coverage of the mechanisms, evidence, and investigative directions relevant to this system
Lixisenatide (Lyxumia ) has no effect on QTc interval in healthy subjects: a thorough QTc study
The NF-kB connection GLP-1 receptor activation, whether by natural GLP-1 or pharmaceutical agonists, inhibits the nuclear factor kappa-B (NF-kB) inflammatory pathway
US$ 26.39
US$ 23.64
US$ 26.33
US$ 29.57
US$ 23.03
US$ 25.07
